4//SEC Filing
Cadavid Diego 4
Accession 0000899243-20-015623
CIK 0001680581other
Filed
Jun 7, 8:00 PM ET
Accepted
Jun 8, 4:17 PM ET
Size
15.2 KB
Accession
0000899243-20-015623
Insider Transaction Report
Form 4
Cadavid Diego
See Remarks
Transactions
- Sale
Common Stock
2020-06-04$20.05/sh−226$4,531→ 66,785 total - Exercise/Conversion
Stock Option (right to buy)
2020-06-05−451→ 14,137 totalExercise: $4.83Exp: 2028-07-10→ Common Stock (451 underlying) - Exercise/Conversion
Common Stock
2020-06-04$4.83/sh+226$1,092→ 67,011 total - Exercise/Conversion
Common Stock
2020-06-05$4.83/sh+451$2,178→ 67,236 total - Sale
Common Stock
2020-06-05$20.18/sh−451$9,101→ 66,785 total - Exercise/Conversion
Stock Option (right to buy)
2020-06-04−226→ 14,588 totalExercise: $4.83Exp: 2028-07-10→ Common Stock (226 underlying)
Footnotes (4)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $20.31, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022.
Documents
Issuer
Fulcrum Therapeutics, Inc.
CIK 0001680581
Entity typeother
Related Parties
1- filerCIK 0001778713
Filing Metadata
- Form type
- 4
- Filed
- Jun 7, 8:00 PM ET
- Accepted
- Jun 8, 4:17 PM ET
- Size
- 15.2 KB